AI-generated · cited to primary sources · not investment advice
Intuitive Surgical, Inc. - Common Stock (ISRG) Jun 2026 Filing Analysis
Does management do what it says?
While the 2025 full-year total is not explicitly restated, the 10-Q confirms that capital expenditures did increase in 2025 as planned to build infrastructure. (1 met across 1 tracked commitment)
“We intend to continue to fund our capital investments with cash generated from operations.”
The phased launch is progressing with significant momentum; da Vinci 5 placements reached 240 units in Q3 2025, up from 110 in Q3 2024. Regulatory clearances were also expanded to Japan and Europe during the period. (2 in progress across 2 tracked commitments)
“We expect that our OUS procedures and revenue will make up a greater portion of our business in the long term.”
Management expects depreciation expense to continue increasing throughout the remainder of 2026. (+1 more commitment)
“We expect depreciation expense to continue to increase in the remainder of 2026.”
The company plans to seek FDA clearances for additional indications for the da Vinci SP surgical system. (+4 more commitments)
“We plan to seek FDA clearances for additional indications for the da Vinci SP surgical system and expand the system’s regulatory approvals (including for additional indications) in other OUS geographic markets over time.”
The company is transitioning to a direct sales model in Italy, Spain, and Portugal following a recent acquisition.
“As a result of the acquisition, Intuitive assumed direct distribution responsibilities for Italy, Spain, Portugal, Malta, San Marino, and associated territories.”
See the full cited Management analysis of Intuitive Surgical, Inc. - Common Stock
How durable is the business?
Revenue from instruments and accessories grew 20% year-over-year, maintaining its position as the primary revenue engine, driven by a 19% increase in da Vinci procedure volume and a 52% jump in Ion procedures. (5 expanding)
“U.S. $ 1,933.2... % of Revenue — U.S. 67%”
Service revenue grew 20% as the installed base of systems expanded to 10,763 units, providing a stable recurring income stream. (3 expanding across 1 engine)
“Instruments and accessories $ 1,734.9... 18%... Product gross profit margin 67.9%”
The technological moat is widening with the rollout of the da Vinci 5, which features 10,000 times the computing power of previous models and new 'force feedback' capabilities. (4 expanding)
“We offer advanced instrumentation for the da Vinci 5, da Vinci X, and da Vinci Xi surgical systems... we have introduced a unique set of force feedback instruments that are only compatible with our da Vinci 5 surgical system.”
The balance sheet remains exceptionally strong with $8.43 billion in liquidity, despite $2.1 billion in share repurchases during the first nine months of 2025. (3 stable, 1 expanding)
“Cash and cash equivalents $ 2,760.4... Short-term investments 2,455.8... Long-term investments 3,409.3... Total liabilities 2,578.9”
The U.S. market share slightly increased to 68% of total revenue, up from 67% in 2024, despite strong international growth, largely due to the rapid adoption of the new da Vinci 5 system in domestic hospitals. (1 expanding across 1 engine)
“Systems 685.0... 19%... Product gross profit margin 67.9%”
See the full cited Business Model analysis of Intuitive Surgical, Inc. - Common Stock
Where does growth come from?
The rollout of the next-generation da Vinci 5 system is in a massive acceleration phase, jumping from only 8 placements in the prior year's quarter to 147 in Q1 2025. (5 accelerating across 5 signals, 1 leading indicator)
“The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems compared to 180 systems in the second quarter of 2025. ... As of June 30, 2026, we have an installed base of 1,710 da Vinci 5 surgical systems.”
Ion procedure growth is accelerating significantly as the installed base expands and utilization increases, with a 73% increase in procedures this quarter compared to the same period last year. (3 accelerating, 2 decelerating across 5 signals)
“Approximately 889,000 da Vinci procedures were performed during the three months ended June 30, 2026, an increase of 15% compared to approximately 775,000 da Vinci procedures for the three months ended June 30, 2025.”
The company is successfully shifting its business model toward leasing to provide customer flexibility, with the percentage of systems placed under lease increasing from 49% to 54%. (1 accelerating, 4 steady across 5 signals)
“Recurring revenue represents the revenue recognized from instruments and accessories, service, and operating lease arrangements. ... % of Total revenue: 85%.”
The company is investing heavily in future technology, with R&D spending increasing to support new robotic platforms and digital healthcare tools.
“Research and development expenses for the three months ended June 30, 2026, increased... primarily driven by higher direct project costs incurred to support an expanded portfolio of product development initiatives.”
The company is securing new regulatory clearances for its 'Single-Port' (SP) system, allowing for surgeries through a single small incision in new markets like Taiwan.
“In August 2024, we obtained regulatory clearance in Taiwan for our da Vinci SP surgical system for use in endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, transanal total mesorectal excision, and breast surgical procedures.”
See the full cited Future Growth analysis of Intuitive Surgical, Inc. - Common Stock
What could break the thesis?
The risk is stable at a high level. The anti-corruption campaign contributed to fewer system placements in 2025 than anticipated, and the impact remains uncertain for future periods. (2 stable, 1 intensifying, 1 high-severity)
“In addition, system demand in China has been adversely affected by increasing competition from domestic robotic-assisted surgical system manufacturers as well as a broader central government focus on systematic governance... this campaign was initially launched by the Chinese government in July 2023 and has resulted in heightened scrutiny by medical institutions with respect to initiating tenders.”
The risk remains high and stable; while Intuitive won a trial against SIS in early 2025, that case is now on appeal, and a separate major class action ('Larkin') was granted class certification in March 2025, increasing potential liability scale. (4 stable, 1 high-severity)
“The Court also ruled that there is an antitrust aftermarket for the repair and replacement of EndoWrist instruments, and that Intuitive holds monopoly power in that aftermarket.”
The risk is intensifying as new tariffs imposed in early 2025 on imports from Mexico, Germany, and China increased cost of revenues by $22 million in Q3 2025 alone, compared to $48.8 million for the entire first half of the prior year. (4 intensifying, 1 stable, 1 high-severity)
“During the three and six months ended June 30, 2026, tariffs and other trade measures recognized in total cost of revenue were $20.8 million and $48.8 million, respectively.”
The risk is stable but remains a significant headwind; management notes that demand in China continues to be adversely impacted by domestic competition and a 'broader central government focus on systematic governance.' (1 stable, 1 intensifying)
“Third parties have offered, and may continue to offer, customers instruments and accessories that have been remanufactured and/or are unauthorized... could potentially result in reduced revenue, increased patient safety risks, and negative publicity.”
The risk is easing slightly in terms of revenue mix volatility; the proportion of da Vinci systems placed under operating leases fell to 54% in Q3 2025 from 58% in Q3 2024, though the total leased installed base continues to grow. (1 easing, 1 stable, 2 intensifying)
“% of Total da Vinci surgical system placements [under leasing] 54% [in 2026] 49% [in 2025]... as a proportion of total system placements increases, total systems revenue is reduced, which can create volatility in the systems revenue recognized in any given period.”
See the full cited Risk analysis of Intuitive Surgical, Inc. - Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.